- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04567173
Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19 (Co-CLARITY)
May 17, 2022 updated by: Deonne Thaddeus Gauiran, University of the Philippines
A Randomized, Open-Label, Single Center Clinical Trial to Assess the Efficacy and Safety of Convalescent Plasma to Hospitalized Adult COVID-19 Patients as Adjunctive Therapy to Reduce the Need for ICU Admission: Co-CLARITY Trial
This protocol provides access to investigational convalescent plasma for hospitalized patients with COVID-19.
Following provision of informed consent, patients will be administered around 500 mL of convalescent plasma obtained from an individual who has recovered from a documented SARS-CoV-2 infection.
The study aims to evaluate the efficacy and safety of anti-SARS-CoV-2 convalescent plasma as adjunctive therapy in preventing disease progression (prevention of ICU admission) among hospitalized patients with COVID-19.
Safety outcomes include serious adverse events judged to be related to convalescent plasma.
Other information which will be collected includes patient demographics and clinical data which includes quick SOFA scores, ventilator-free days, ICU-free days, dialysis-free days and 28-day mortality.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
This is a phase 3, randomized, non-placebo controlled, open-label, single-center clinical trial which will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma given from the 3rd to 14th day of illness after the onset of symptoms in preventing ICU admission among hospitalized COVID-19 patients compared to standard of care.
Consecutive patients with COVID-19 admitted to the UP Philippine General Hospital will be offered participation into the study.
Patients in the intervention group will receive one dose of type-specific anti-SARS-CoV-2 convalescent plasma (500 mL collected by whole blood donation or standard pheresis at the UP-PGH blood bank from a volunteer who recovered from COVID-19).
The primary safety endpoints include serious adverse events judged to be related to convalescent plasma.
The study also aims to compare anti-SARS-CoV-2 antibody titers and rates, levels, and duration of SARS-CoV-2 RNA in nasopharyngeal swabs using RT-PCR between the intervention and control groups.
Study Type
Interventional
Enrollment (Actual)
44
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Manila, Philippines, 1000
- UP Philippine General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient must be 19 years of age or older
- Hospitalized with COVID-19 and confirmed via SARS-CoV-2 RT-PCR testing
- Patient is willing and able to provide written consent and comply with all protocol requirements
- Patient agrees to storage of specimens for future testing
Exclusion Criteria:
- Female subjects with positive pregnancy test, are breastfeeding or planning to become pregnant/breastfeed during the study period
- Symptomatic illness exceeding 14 days from onset of illness at time of enrollment
ICU admission on initial presentation at the hospital (includes patients with clinical indications for ICU admission as follows:
- Respiratory distress with requirement of O2 >6 lpm to maintain O2 sat >92%
- Rapid escalation of O2 requirement/significant work of breathing
- Hemodynamic instability: SBP <90, MAP <65
- Receipt of any blood products including pooled immunoglobulin or intravenous immunoglobulin (IVIg) in the past 30 days prior to enrolment
- Known IgA deficiency
- Presence of any contraindication to transfusion (or history of prior severe reactions to transfusion of blood products)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anti-SARS-CoV-2 convalescent plasma
About 500 mL of type-specific anti-SARS-CoV-2 convalescent plasma collected by whole blood donation or standard pheresis from a volunteer who recovered from COVID-19 transfused intravenously as 2 aliquots of 250 mL
|
convalescent plasma derived from whole blood donors or standard pheresis from a volunteer who recovered from COVID-19
|
No Intervention: Standard of care
Patients in the control group are those will only receive local standard of care as deemed appropriate by the primary attending physicians and guided by institutional pathways
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of serious adverse events
Time Frame: 28 days from enrollment
|
Cumulative incidence of serious adverse events (transfusion-related acute lung injury, transfusion associated circulatory overload, transfusion related infection and anaphylaxis/severe allergic reactions) during the study period
|
28 days from enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quick SOFA (qSOFA) score
Time Frame: 28 days from enrollment
|
Quick Sequential Organ Failure Assessment (qSOFA) scores of study participants within 28 days from enrollment.
The qSOFA score is a rapid bedside clinical score used to identify patients with suspected infection that are at a greater risk for a poor outcome.
Minimum score is 0 and maximum score is 3.
A higher score is associated with higher risk for in-hospital mortality.
|
28 days from enrollment
|
Cardiopulmonary arrest
Time Frame: 28 days from enrollment
|
Total number of patients experiencing cardiopulmonary arrest
|
28 days from enrollment
|
ICU mortality
Time Frame: 28 days from enrollment
|
Total number of deaths among patients admitted to the ICU
|
28 days from enrollment
|
ICU length of stay
Time Frame: 28 days from enrollment
|
Total number of days patients were admitted to the ICU
|
28 days from enrollment
|
Hospital mortality
Time Frame: 28 days from enrollment
|
Total number of deaths among study participants
|
28 days from enrollment
|
Hospital length of stay
Time Frame: 28 days from enrollment
|
Total number of days patients were admitted to the hospital
|
28 days from enrollment
|
Dialysis-free days
Time Frame: 28 days from enrollment
|
Days without dialysis within 28 days from enrollment
|
28 days from enrollment
|
Vasopressor-free days
Time Frame: 28 days from enrollment
|
Days without vasopressors within 28 days from enrollment
|
28 days from enrollment
|
ICU-free days
Time Frame: 28 days from enrollment
|
Days without need for ICU admission within 28 days from enrollment
|
28 days from enrollment
|
28-day mortality
Time Frame: 28 days from enrollment
|
Total number of patient deaths within 28 days from enrollment
|
28 days from enrollment
|
Anti-SARS-CoV-2 antibody titers
Time Frame: days 0, 1, 7 and 14 of enrollment
|
Anti-SARS-CoV-2 IgG antibody titers
|
days 0, 1, 7 and 14 of enrollment
|
SARS-CoV-2 RNA by RT-PCR
Time Frame: days 0, 1, 7 and 14 of enrollment
|
Levels of SARS-CoV-2 RNA in nasopharyngeal swabs (or other specimen types as available) using RT-PCR
|
days 0, 1, 7 and 14 of enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Deonne Thaddeus V Gauiran, MD, UP Philippine General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 21, 2020
Primary Completion (Actual)
June 30, 2021
Study Completion (Actual)
June 30, 2021
Study Registration Dates
First Submitted
September 24, 2020
First Submitted That Met QC Criteria
September 24, 2020
First Posted (Actual)
September 28, 2020
Study Record Updates
Last Update Posted (Actual)
May 24, 2022
Last Update Submitted That Met QC Criteria
May 17, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PHRR200824-002868
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Anti-SARS-CoV-2 convalescent plasma
-
Noah MerinJohns Hopkins UniversityTerminatedCovid-19 | Sars-CoV2United States
-
Thomas BenfieldTerminatedCOVID | Corona Virus Infection | Viral PneumoniaDenmark
-
Orthosera Kft.University of Pecs; Semmelweis University; Hungarian National Blood Service; Humán...Recruiting
-
Medical College of WisconsinFroedtert HospitalCompletedCOVID-19United States
-
U.S. Army Medical Research and Development CommandNo longer availableTreatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)Severe Acute Respiratory Syndrome Coronavirus 2United States, Germany, Afghanistan, Djibouti, Guam, Iraq, Japan, Kuwait
-
Institute for Transfusion Medicine of RNMUniversity Clinic for Infectious Diseases, North MacedoniaCompletedCOVID-19 | SARS-CoV 2 | Convalescent PlasmaNorth Macedonia
-
Ascension South East MichiganWithdrawn
-
Joakim DillnerKarolinska University Hospital; Karolinska Institutet; Danderyd HospitalCompleted
-
Johns Hopkins UniversityCompletedSARS-CoV-2 InfectionUnited States